San Francisco 30 April 2019
The Report “Psoriasis Drugs Market Analysis Report by Therapeutic Class (Interleukin-inhibitors,
Tumor Necrosis Factor-inhibitors), by Treatment (Topicals, Systemic,
Biologics), and Segment Forecasts, 2016 – 2022”
The global psoriasis drugs market size is expected to be valued at USD 21.11 billion by
2022, as per a new report by Grand View Research, Inc., experiencing a CAGR of
9.4% during the forecast period. Rising disease awareness, increasing number of
reimbursement strategies for biologics, and advanced diagnostic and
technological tools are likely to increase the adoption of psoriasis
therapeutics.
Additionally, expanding base of patients
suffering from psoriasis is anticipated to fuel growth prospects. The exact
causative factors for psoriasis are undetermined; however, certain genetic and
environmental factors may trigger the disease onset. Most available treatments
aim to decelerate disease progression by stopping hyperproliferation of
keratinocyte.
Psoriasis can be classified into five types:
plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms
of site of disease and characterization of lesions. Erythrodermic psoriasis is
the rarest and plaque psoriasis is the most prevalent type affecting patients
all over the world.
Incidence rate of psoriasis has witnessed a
gradual rise over the years across various geographical locations. This
increase can be attributed to genetic and environmental triggers as well as
lifestyle changes. Rise in prevalence rates could also be associated with
declining response or developing resistance to therapies for disease control.
Access Research Report of Psoriasis Drugs Market @ https://www.grandviewresearch.com/industry-analysis/psoriasis-drugs-market
Further key findings from the report suggest:
· Tumor Necrosis Factor-inhibitors dominated
the market in 2016 owing to its higher usage by healthcare practitioners and
easy availability
· TNF-inhibitors are likely to lose market
shares over the forecast period due to increasing preference for IL-inhibitor
therapy to conventional TNF-inhibitors
· Interleukin-inhibitors is expected to
register a lucrative CAGR of over 21.0% during the forecast period owing to
improved safety and efficacy profiles of Interleukin-inhibiting drugs
· The U.S is the dominant region in the
psoriasis market in terms of revenue in 2016 due to increasing number of
patients seeking treatment and presence of well-established healthcare services
· Japan is expected to be the fastest growing
region during the same period due to growing awareness about the disease among
the populace
· Some of the key players in this industry
are AbbVie Inc.; Amgen Inc.; Johnson & Johnson; Novartis AG; Eli Lilly
& Company; AstraZeneca; Celgene Corporation; UCB; and Merck.
Browse more reports of this category by Grand View
Research at: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has
segmented the global psoriasis drugs market based on therapeutic class,
treatment, and region:
Therapeutic Class Outlook (Revenue, USD
Million, 2016 - 2022)
·
Tumor Necrosis Factor Inhibitor
·
Interleukin Inhibitors
·
Others
Treatment Outlook (Revenue, USD Million,
2016 - 2022)
·
Topicals
·
Systemic
·
Biologics
Regional Outlook (Revenue, USD Million,
2016 - 2022)
·
U.S.
·
U.K.
·
Germany
·
Spain
·
France
·
Italy
·
Japan
Access Press Release of
Psoriasis Drugs Market@ https://www.grandviewresearch.com/press-release/global-psoriasis-drugs-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment